NSE AUROPHARMA · BSE 524804 · Major Drugs · NIFTY 500

Aurobindo Pharma Share Price

Market closed · NSE price as of Mon 28 Sep
₹1,697.50 ▼ −₹14.55 · 0.85%
Day range · 28 Sep
₹1,687.60Low₹1,723.35High
52-week range
₹1,066.00Low · 8 Oct 2025₹1,739.60High · 24 Sep 2026

Aurobindo Pharma Overview

Where the price stands, how it has moved and how it sits against its averages.

Aurobindo Pharma shares last traded at ₹1,697.50 on the NSE, down 0.85% on the day. That is 2.4% below the 52-week high of ₹1,739.60 and 59.2% above the 52-week low of ₹1,066.00. The stock trades at 26.31× earnings, below the sector average of 33.72. Its market value is ₹97,670 Cr.

NSE closing prices — daily for the last year, weekly before that — ending at the latest price (Mon 28 Sep). Hover, tap or use the arrow keys to read a day.

Price returns

1 Day▼ −0.85%
1 Week▼ −0.93%
This month▼ −1.14%
3 Months▲ +9.15%
6 Months▲ +29.17%
This year▲ +43.49%
1 Year▲ +55.65%

Share price growth a year (CAGR): 3 years ▲ +25.1% · 5 years ▲ +18.6% · 10 years ▲ +7.3%

Against the market: 1 Month ▲ +8.80% · 3 Months ▲ +14.86% · 6 Months ▲ +29.72% · This year ▲ +66.90% · 1 Year ▲ +71.40%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Mon 26 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 5 of 6

  1. 5-day average₹1,712.58 ▼ price 0.9% below
  2. Today's price₹1,697.50
  3. 10-day average₹1,696.97 ▲ price 0.0% above
  4. 20-day average₹1,682.51 ▲ price 0.9% above
  5. 50-day average₹1,630.81 ▲ price 4.1% above
  6. 100-day average₹1,564.34 ▲ price 8.5% above
  7. 300-day average₹1,401.52 ▲ price 21.1% above

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

Aurobindo Pharma Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
33,653
Net profit₹ crore · losses below zero
5,335
3,505

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹33,653 Cr ▲ +6.1% ₹3,505 Cr 10.4% ₹60.34 —
FY 2025 ₹31,724 Cr ▲ +9.4% ₹3,486 Cr 11.0% ₹59.81 ₹0.00
FY 2024 ₹29,002 Cr ▲ +16.7% ₹3,173 Cr 10.9% ₹54.15 ₹4.50
FY 2023 ₹24,855 Cr ▲ +6.0% ₹1,928 Cr 7.8% ₹32.90 ₹3.00
FY 2022 ₹23,455 Cr ▼ −5.3% ₹2,648 Cr 11.3% ₹45.20 ₹9.00
FY 2021 ₹24,775 Cr ▲ +7.3% ₹5,335 Cr 21.5% ₹91.05 ₹4.00
FY 2020 ₹23,099 Cr — ₹2,845 Cr 12.3% ₹48.56 ₹3.00

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
35%
65%
  • Total assets₹58,502 Cr
  • Total liabilities₹20,611 Cr
  • Shareholders' equity₹37,891 Cr
  • Total debt₹8,073 Cr
  • Cash & investments₹10,585 Cr
  • Current ratio1.81×
  • Revenue growth, 5 yr6.32% a year
  • EPS growth, 5 yr−7.90% a year
  • Operating margin (TTM)14.77%
  • Net margin (TTM)10.62%

Cash flow — FY26

Operating activities
▲ ₹5,527 Cr
Investing activities
▼ −₹3,459 Cr
Financing activities
▼ −₹1,269 Cr
Free cash flow
▲ ₹2,422 Cr
Net change in cash
▲ ₹1,628 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue23,098.5124,774.6223,455.4924,855.3829,001.8731,723.7333,653.08
Cost of revenue10,611.9110,805.2811,053.5012,325.9013,660.1514,316.1614,926.79
Gross profit12,486.6013,969.3412,401.9912,529.4815,341.7217,407.5718,726.29
Operating expenses19,190.0017,540.9120,399.2222,341.7424,871.4026,767.6528,616.35
Operating income3,908.517,233.713,056.272,513.644,130.474,956.085,036.73
Depreciation966.711,055.391,126.521,244.581,491.911,633.971,760.65
Profit before tax3,743.047,343.593,372.742,612.504,379.995,066.295,111.85
Tax899.352,009.77725.63684.851,211.021,582.721,608.88
Net profit2,845.145,334.842,648.151,927.503,172.973,485.893,504.75
EPS (₹)48.5691.0545.2032.9054.1559.8160.34
Dividend per share (₹)3.004.009.003.004.500.00—

Aurobindo Pharma vs Peers

Side by side with other major drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
Aurobindo Pharma This stock ₹1,697.50 ▼ −0.85% ₹97,670 Cr 26.31 2.60 10.25% 10.62% 0.00%
Neuland Laboratories ₹21,410.85 ▼ −2.25% ₹27,364 Cr 64.28 12.62 19.28% 17.99% 0.18%
Pfizer ₹3,975.00 ▼ −0.76% ₹18,180 Cr 27.53 4.97 19.08% 28.67% 1.64%
Unichem Laboratories ₹538.95 ▼ −2.04% ₹3,762 Cr 54.27 1.53 1.01% 11.48% —
Jagsonpal Pharmaceuticals ₹238.60 ▼ −1.73% ₹1,570 Cr 34.27 5.43 18.10% 15.00% 1.12%
Themis Medicare ₹116.65 ▼ −0.38% ₹1,071 Cr 632.19 2.54 11.91% 0.33% 0.45%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns Aurobindo Pharma shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
51.9%
16.4%
16.7%
15.0%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter51.82%51.82%51.82%51.88% ▲ +0.06 pts
FII14.21%13.95%15.24%16.38% ▲ +1.14 pts
MF19.30%19.52%17.79%16.71% ▼ −1.08 pts
Other14.67%14.71%15.15%15.03% ▼ −0.12 pts

Aurobindo Pharma Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Aurobindo PharmaBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
26.31
▼ 22% below the sector average of 33.72
P/E, 12-month rangeLow 8.14 · high 24.67
100%
Today's P/E sits 100% of the way from its low to its high
P/BPrice ÷ book value per share
2.60
P/SMarket cap ÷ last 12 months' revenue
2.80
P/CFPrice ÷ cash flow per share
17.68
PEGP/E ÷ earnings growth rate
1.19

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
60.28%
▲ above its 5-yr average of 53.55%
Operating marginKept after running costs
14.77%
▲ above its 5-yr average of 13.80%
Pre-tax marginKept before tax
15.51%
▲ above its 5-yr average of 14.40%
Net marginKept as profit
10.62%
▲ above its 5-yr average of 10.32%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
9.94%
▼ below its 5-yr average of 10.25%
Return on assetsProfit on everything it owns
6.47%
▼ below its 5-yr average of 6.86%
Return on investmentProfit on long-term capital
9.27%
▼ below its 5-yr average of 9.57%
Return on capital employedProfit before interest and tax on equity + debt
11.83%

Growth Is the business getting bigger?

Revenue — last 12 months
+9.1%
▲ growing
Revenue — 3 yr, a year
+10.6%
▲ growing
Revenue — 5 yr, a year
+6.3%
▲ growing
Net profit — 3 yr, a year
+22.1%
▲ growing
Net profit — 5 yr, a year
−8.1%
▼ shrinking
EPS — last 12 months
+9.8%
▲ growing
EPS — 3 yr, a year
+22.4%
▲ growing
EPS — 5 yr, a year
−7.9%
▼ shrinking
Book value — 5 yr, a year
+11.8%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.21×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
1.81×
✓ Comfortable
Quick ratioLike the current ratio, without inventory
1.15×
✓ Comfortable
Interest coverOperating profit ÷ interest to pay
183.39×
✓ Strong
Payout ratioShare of profit paid as dividend
0.00%
• Keeps most

Per share What each share stands for

EPS (TTM)
₹64.00
Book value
₹652.39
Cash flow
₹96.01
Dividend
₹0.00
Revenue
₹602.19

The share price is 2.60× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 107 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year28.37
Current Dividend Yield - Common Stock Primary Issue, LTM0.00
Price to Book - most recent fiscal year2.62
P/E Basic excluding extraordinary items - TTM24.67
P/E including extraordinary items - TTM26.75
P/E excluding extraordinary items low, trailing 12 months8.14
Price to Tangible Book - most fiscal year3.02
Price to sales - most recent fiscal year2.93
Dividend Yield - indicated annual dividend divided by closing price0.23
Price to Cash Flow per share - trailing 12 month17.68
Peg Ratio1.19
Price to Free Cash Flow per Share - most recent fiscal year44.99
P/E Normalized, most recent fiscal year27.62
P/E excluding extraordinary items high, trailing 12 months24.67
P/E excluding extraordinary items, most recent fiscal year quarter26.75
Price to sales - trailing 12 month2.82
Net Debt, LFY−25,120.80

Per share

Cash Flow per share - trailing 12 month96.01
Cash Flow per share - most recent fiscal year90.63
EPS including extraordinary items - trailing 12 month64.00
EPS including extraordinary items - most recent fiscal year60.34
EBITD per share - trailing 12 month122.79
Revenue/share - trailing 12 month602.19
EPS excluding extraordinary items - trailing 12 month64.00
EPS Basic excluding extraordinary items - most recent fiscal year60.34
EPS Basic excluding extraordinary items - trailing 12 month64.00
Book value per share - most recent fiscal year652.39
Revenue/share - most recent fiscal year579.42
EPS Normalized - most recent fiscal year61.98
Book value (tangible) per share - most recent fiscal year561.46
Dividends per share - trailing 12 month0.00
EPS excluding extraordinary items - most recent fiscal year60.34
Cash per share - most recent fiscal year182.25

Margins

Operating margin - trailing 12 month14.77
Gross Margin - 5 year average53.55
Operating margin - 1st historical fiscal year14.97
Operating Margin - 5 year average13.80
Net Profit Margin % - 1st historical fiscal year10.41
Gross Margin - 1st historical fiscal year55.65
Net Profit Margin % - trailing 12 month10.62
Net Profit Margin - 5 year average10.32
Pretax Margin - 5 year average14.40
Pretax margin - 1st historical fiscal year15.19
Pretax margin - trailing 12 month15.51
Free Operating Cash Flow/Revenue, 5 Year Average2.44
Gross Margin - trailing 12 month60.28

Growth

EPS Change %, TTM over TTM9.75
Revenue growth rate, 5 year6.32
EPS growth rate, 5 year−7.90
Revenue Change % - most recent quarter 1 year ago16.30
Growth rate% - EPS, 3 year22.41
Revenue/share (5 yr growth)6.50
Free Operating Cash Flow, 5 Year CAGR11.98
Tangible Book Value, Total Equity, 5 Year CAGR11.63
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR6.15
Capital Spending growth rate, 5 year10.63
Revenue Change %, TTM over TTM9.09
Growth rate% - Revenue, 3 year10.63
Book value per share growth rate, 5 year11.75
EPS Change % - most recent quarter 1 year ago25.77
Net Profit Margin growth rate, 5 year−13.53
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR4.77
Total Debt, 5 Year CAGR8.41

Financial strength

Net Interest coverage - most recent fiscal year183.39
Free Cash Flow - most recent fiscal year21,894.80
LT debt/equity - most recent fiscal year0.03
Quick ratio - most recent fiscal year1.15
Payout ratio - trailing 12 month0.00
Current ratio - most recent fiscal year1.81
Current EV/Free Cash Flow, LFY49.82
Total debt/total equity - most recent fiscal year0.21
Net Interest coverage - trailing 12 month17.62

Returns & efficiency

Return on average equity - 5 year average10.25
Net Income/employee - trailing 12 month12,70,430.00
Revenue/employee - most recent fiscal year1,18,25,530.00
Return on investment - most recent fiscal year9.27
Return on average assets - most recent fiscal year6.47
Receivables turnover - most recent fiscal year5.18
Inventory turnover - most recent fiscal year1.32
Revenue/employee - trailing 12 month1,19,60,450.00
Return on average assets - 5 year average6.86
Net Income/employee - most recent fiscal year12,30,926.00
Asset turnover - most recent fiscal year0.62
Return on average equity - most recent fiscal year9.94
Return on investment - 5 year average9.57

Price & volume

Market Cap97,814.24
52 week Low Date8 Oct 2025
Price - 1 Day % Change−0.23
Relative (S&P500) price percent change - 13 week14.86
Avg trading volume last 10 days0.76
Price - 13 week price percent change10.08
Price - 52 week price percent change56.06
Avg Trading Volume Last 3 months21.08
Price - 5 Day % Change−1.27
Price % Change Month To Date−0.29
Relative (S&P500) price percent change - 04 week8.80
52 week High Date24 Sep 2026
Price - 26 week price percent change30.27
PDATE25 Sep 2026
Price - YTD price percent change44.72
Relative (S&P500) price percent change - 52 week71.40
NPRICE1,712.00
Relative (S&P500) price percent change - 26 week29.72
52 week Low1,066.80
52 week High1,740.00
Beta0.89
Relative (S&P500) price percent change - Year to Date66.90

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹9.00
₹0.00
  • Dividend yield0.00%
  • Payout ratio0.00%
  • Latest dividend₹4.00 per share · 8 Aug 2025

Corporate calendar

  • MeetingAnnual General Meeting
  • BoardQuarterly Results
  • BoardAudited Results
  • BoardBuy Back of Shares
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
Show 14 older events
  • Dividend₹4.00 per share · 400% · Interim dividend
  • BoardQuarterly Results & Interim Dividend
  • BoardAudited Results
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • MeetingPostal Ballot
  • Dividend₹1.50 per share · 150% · Interim dividend
  • Dividend₹3.00 per share · 300% · Interim dividend
  • Dividend₹3.00 per share · 300% · Interim dividend
  • Dividend₹4.50 per share · 450% · Interim dividend
  • Dividend₹1.50 per share · 150% · Interim dividend
  • Dividend₹1.50 per share · 150% · Interim dividend
  • Dividend₹1.50 per share · 150% · Interim dividend

About Aurobindo Pharma

Major Drugs

Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.

Key people

  • Kambam Nithyananda ReddyExecutive Vice Chairman of the Board, Managing Director, Promoter
  • Santhanam SubramanianChief Financial Officer
  • Baddigam Adi ReddyCompliance Officer, Company Secretary
  • Mettu Madan Mohan ReddyWhole-Time Director

Company facts

  • NSE symbolAUROPHARMA
  • BSE code524804
  • ISININE406A01037
  • IndustryMajor Drugs
  • IndexNIFTY 500
  • Market cap₹97,670 Cr
  • Revenue (FY26)₹33,653 Cr
  • Net profit (FY26)₹3,505 Cr

In the News

Recent headlines about Aurobindo Pharma — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

Aurobindo Pharma (NSE: AUROPHARMA) last traded at ₹1,697.50 on the NSE, down 0.85% (₹14.55) on the day, as of 28 Sep 2026. The day's range was ₹1,687.60 – ₹1,723.35.

Aurobindo Pharma's 52-week high is ₹1,739.60 (24 Sep 2026) and its 52-week low is ₹1,066.00 (8 Oct 2025). At ₹1,697.50 the share is 2.4% below its high and 59.2% above its low.

Aurobindo Pharma's market capitalisation is ₹97,670 Cr (₹97,670 Cr). It is part of the NIFTY 500 index.

Aurobindo Pharma's P/E ratio (trailing 12 months) is 26.31. The sector average is 33.72, so investors pay 22% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹64.00.

Aurobindo Pharma shares are up 55.65% over the last year, up 43.49% so far this year, up 29.17% over 6 months, up 9.15% over 3 months. Over the last year the stock did 71.40% better than the market.

In FY26 (year to Mar 2026), Aurobindo Pharma reported revenue of ₹33,653 Cr (up 6.08% on the year before) and a net profit of ₹3,505 Cr. Earnings per share were ₹60.34.

Yes. Aurobindo Pharma's latest dividend is ₹4.00 per share (400%, interim dividend), with an ex-date of 8 Aug 2025. The dividend yield is 0.00%. It has paid 8 dividends in the records shown on this page.

As of Jun 2026: Promoter 51.88%, FII 16.38%, MF 16.71%, Other 15.03%. Promoter holding rose by 0.06 percentage points from Mar 2026.

Aurobindo Pharma's listed peers in Major Drugs include Neuland Laboratories, Pfizer, Unichem Laboratories, Jagsonpal Pharmaceuticals, Themis Medicare. By market capitalisation it ranks #1 of 6 in this group.

No. Aurobindo Pharma has debt — its debt-to-equity ratio is 0.21 and total debt was ₹8,073 Cr in FY26. Its operating profit covers interest 183.39 times.